185 related articles for article (PubMed ID: 32281790)
1. Site-Specific Antibody Conjugation Strategy to Functionalize Virus-Based Nanoparticles.
Park J; Chariou PL; Steinmetz NF
Bioconjug Chem; 2020 May; 31(5):1408-1416. PubMed ID: 32281790
[TBL] [Abstract][Full Text] [Related]
2. Bioconjugation of Active Ingredients to Plant Viral Nanoparticles Is Enhanced by Preincubation with a Pluronic F127 Polymer Scaffold.
Shin MD; Hochberg JD; Pokorski JK; Steinmetz NF
ACS Appl Mater Interfaces; 2021 Dec; 13(50):59618-59632. PubMed ID: 34890195
[TBL] [Abstract][Full Text] [Related]
3. Viral nanoparticles for in vivo tumor imaging.
Wen AM; Lee KL; Yildiz I; Bruckman MA; Shukla S; Steinmetz NF
J Vis Exp; 2012 Nov; (69):e4352. PubMed ID: 23183850
[TBL] [Abstract][Full Text] [Related]
4. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
Shen BQ; Xu K; Liu L; Raab H; Bhakta S; Kenrick M; Parsons-Reponte KL; Tien J; Yu SF; Mai E; Li D; Tibbitts J; Baudys J; Saad OM; Scales SJ; McDonald PJ; Hass PE; Eigenbrot C; Nguyen T; Solis WA; Fuji RN; Flagella KM; Patel D; Spencer SD; Khawli LA; Ebens A; Wong WL; Vandlen R; Kaur S; Sliwkowski MX; Scheller RH; Polakis P; Junutula JR
Nat Biotechnol; 2012 Jan; 30(2):184-9. PubMed ID: 22267010
[TBL] [Abstract][Full Text] [Related]
5. TLR Agonists Delivered by Plant Virus and Bacteriophage Nanoparticles for Cancer Immunotherapy.
Jung E; Chung YH; Steinmetz NF
Bioconjug Chem; 2023 Sep; 34(9):1596-1605. PubMed ID: 37611278
[TBL] [Abstract][Full Text] [Related]
6. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates.
Acchione M; Kwon H; Jochheim CM; Atkins WM
MAbs; 2012; 4(3):362-72. PubMed ID: 22531451
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Antibody Response against Small Molecular Hapten with Tobacco Mosaic Virus as a Polyvalent Carrier.
Zhao X; Chen L; Luckanagul JA; Zhang X; Lin Y; Wang Q
Chembiochem; 2015 Jun; 16(9):1279-83. PubMed ID: 25914312
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeted viral nanoparticles as tools for imaging cancer.
Cho CF; Shukla S; Simpson EJ; Steinmetz NF; Luyt LG; Lewis JD
Methods Mol Biol; 2014; 1108():211-30. PubMed ID: 24243252
[TBL] [Abstract][Full Text] [Related]
9. LASIC: Light Activated Site-Specific Conjugation of Native IgGs.
Hui JZ; Tamsen S; Song Y; Tsourkas A
Bioconjug Chem; 2015 Aug; 26(8):1456-60. PubMed ID: 26057140
[TBL] [Abstract][Full Text] [Related]
10. Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases.
Qasba PK
Bioconjug Chem; 2015 Nov; 26(11):2170-5. PubMed ID: 26065635
[TBL] [Abstract][Full Text] [Related]
11. Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase.
Huggins IJ; Medina CA; Springer AD; van den Berg A; Jadhav S; Cui X; Dowdy SF
Molecules; 2019 Sep; 24(18):. PubMed ID: 31509944
[TBL] [Abstract][Full Text] [Related]
12. Chemical introduction of reactive thiols into a viral nanoscaffold: a method that avoids virus aggregation.
Steinmetz NF; Evans DJ; Lomonossoff GP
Chembiochem; 2007 Jul; 8(10):1131-6. PubMed ID: 17526061
[TBL] [Abstract][Full Text] [Related]
13. Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue.
Corogeanu D; Zaki K; Beavil AJ; Arnold JN; Diebold SS
PLoS One; 2023; 18(3):e0282831. PubMed ID: 36913398
[TBL] [Abstract][Full Text] [Related]
14. Site-Specific Conjugation to Native and Engineered Lysines in Human Immunoglobulins by Microbial Transglutaminase.
Spidel JL; Vaessen B; Albone EF; Cheng X; Verdi A; Kline JB
Bioconjug Chem; 2017 Sep; 28(9):2471-2484. PubMed ID: 28820579
[TBL] [Abstract][Full Text] [Related]
15. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
[TBL] [Abstract][Full Text] [Related]
16. Improving the serum stability of site-specific antibody conjugates with sulfone linkers.
Patterson JT; Asano S; Li X; Rader C; Barbas CF
Bioconjug Chem; 2014 Aug; 25(8):1402-7. PubMed ID: 25099687
[TBL] [Abstract][Full Text] [Related]
17. Site-Specific Antibody Labeling by Covalent Photoconjugation of Z Domains Functionalized for Alkyne-Azide Cycloaddition Reactions.
Perols A; Arcos Famme M; Eriksson Karlström A
Chembiochem; 2015 Nov; 16(17):2522-9. PubMed ID: 26417902
[TBL] [Abstract][Full Text] [Related]
18. Substrate Design Enables Heterobifunctional, Dual "Click" Antibody Modification via Microbial Transglutaminase.
Walker JA; Bohn JJ; Ledesma F; Sorkin MR; Kabaria SR; Thornlow DN; Alabi CA
Bioconjug Chem; 2019 Sep; 30(9):2452-2457. PubMed ID: 31409067
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates.
Dennler P; Chiotellis A; Fischer E; Brégeon D; Belmant C; Gauthier L; Lhospice F; Romagne F; Schibli R
Bioconjug Chem; 2014 Mar; 25(3):569-78. PubMed ID: 24483299
[TBL] [Abstract][Full Text] [Related]
20. Molecularly defined antibody conjugation through a selenocysteine interface.
Hofer T; Skeffington LR; Chapman CM; Rader C
Biochemistry; 2009 Dec; 48(50):12047-57. PubMed ID: 19894757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
